Table 3 Multivariate analysis of prognosis of 157 HCC patients in a TCGA cohort using Cox proportional hazard model

CRHBP

-.267

1.272

.044

1

.834

.766

.063

9.268

DNASE1L3

-.969

.476

4.140

1

.042

.379

.149

.965

FCN2

.517

.896

.333

1

.564

1.676

.290

9.704

INTS8

.204

.090

5.175

1

.023

1.227

1.029

1.463

LCAT

.030

.194

.024

1

.877

1.031

.704

1.509

MARCO

-.070

.859

.007

1

.935

.932

.173

5.020

MT1X

.788

1.051

.561

1

.454

2.198

.280

17.256

PAMR1

-.158

.236

.448

1

.503

.854

.538

1.355

VIPR1

.194

.287

.459

1

.498

1.215

.692

2.131

Stage (I/II–III)

.901

.463

3.784

1

.050

2.462

.993

6.101

PT (1–2/3–4)

-.223

.426

.273

1

.601

.800

.347

1.844

Residual (R0/R1–2)

-.175

.586

.089

1

.765

.839

.266

2.649

Tumour status (free/with)

1.300

.404

10.359

1

.001

3.669

1.662

8.097

Vital status (dead/alive)

−13.599

55.193

.061

1

.805

.000

.000

1.2e + 41

Age

.000

.014

.001

1

.981

1.000

.974

1.028

Gender

-.276

.312

.781

1

.377

.759

.412

1.399